Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2022-08-12 Earnings Release
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and that a press release announcing financial results for the quarter ended June 30, 2022, is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length is 3992 characters, which is relatively short and consistent with a current report filing rather than a full financial report. According to the rules, such a document announcing financial results via a press release and not containing the full financial data should be classified as an Earnings Release (ER).
2022-08-12 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes the submission of matters to a vote of security holders at the 2022 Annual Meeting, detailing voting results on director elections, auditor ratification, a stock split proposal, and adjournment authority. This corresponds to the official results from shareholder votes at a general meeting. The document also references a press release about clinical trial results, but the main focus is the voting results. Therefore, this filing fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail confirm it is not a brief announcement but a full report of voting outcomes. Confidence is high due to explicit SEC form type and detailed vote results.
2022-08-10 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically labeled as "Definitive Additional Materials" related to the Annual Meeting of Stockholders. It contains voting instructions and urges shareholders to vote on proposals, including a Reverse Stock Split Amendment. The content is focused on soliciting shareholder votes and providing proxy voting information rather than presenting financial data or management discussion. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is 2872 characters, which is consistent with a proxy solicitation document rather than a full report. Therefore, the correct classification is PSI.
2022-07-28 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 27, 2022. It includes a Regulation FD Disclosure about a presentation by the Chief Scientific Officer at a conference, with the presentation attached as Exhibit 99.1. The document explicitly states that the information is being furnished and not filed, and the main content is a presentation for an investor or industry conference. There are no financial statements or detailed financial data included. The document length is 3919 characters, which is relatively short and consistent with a report furnishing a presentation rather than a full report. This matches the definition of an Investor Presentation (IP).
2022-07-27 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Definitive Additional Materials filing related to a Proxy Statement (Schedule 14A) for the Annual Meeting of Stockholders. It includes voting instructions and recommendations from the Board of Directors on various proposals, such as election of directors, appointment of auditors, and a reverse stock split amendment. The content is focused on soliciting shareholder votes and providing proxy voting information rather than the proxy statement itself or the voting results. This matches the description of Proxy Solicitation & Information Statement (PSI). The document length is 2600 characters, which is consistent with a solicitation document rather than a full report or voting results announcement.
2022-07-19 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement related to shareholder voting matters. It includes information about the Annual Meeting of Stockholders, voting instructions, and recommendations from the Board of Directors. The text does not contain financial statements or detailed financial performance data, but rather focuses on soliciting votes and providing proxy materials. This matches the description of Proxy Solicitation & Information Statement (PSI). The document length is 2313 characters, which is consistent with a proxy solicitation document rather than a full annual report or other financial filing.
2022-07-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.